Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone–releasing hormone antagonist cetrorelix

Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development.

A. Prader, R. H. Largo, Luciano Molinari et al. · PubMed · 1989 · 683 citations

Education, Human Development, Pediatrics +17

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin

Carola Albano, R. Felberbaum, Johan Smitz et al. · Human Reproduction · 2000 · 312 citations · Full text

Veterinary Medicine, Endocrinology, Gynecology +13

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group

Human Reproduction · 1998 · 293 citations · Full text

Pharmacy, Endocrinology, Pharmacology +17

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)

F. Olivennes, J. Belaïsch-Allart, Jean-Claude Emperaire et al. · Fertility and Sterility · 2000 · 257 citations · Full text

Veterinary Medicine, Obstetrics, Pharmacology +17

Complications of medically assisted conception in 3,500 cycles

Gamal I. Serour, Mohamed Aboulghar, Ragaa Mansour et al. · Fertility and Sterility · 1998 · 154 citations

Medicine, Gynecology, Obstetrics +9